Pharma’s Blame-The-Middleman Strategy Pays Off – For Now
Executive Summary
Success of drug industry’s campaign to highlight role of 'middlemen' in the supply chain was never more clear than during President Trump’s Rose Garden drug pricing event. But what happens now that the attention is turned squarely back on manufacturers?
You may also be interested in...
PCMA’s Merritt Reflects On 15 Years At The Helm Of PBM Advocacy
Outgoing Pharmaceutical Care Management Association chief discusses fight over rebates, future of pharmacy benefit management, opportunities and challenges facing his successor.
PBMs’ Impact On Drug Prices Probed By House Committee Leaders
Letter to seven pharmacy benefit managers seeks insight into pros and cons of practices, suggesting that policymakers understand PBMs bring value in lowering costs but that some activities are counterproductive.
Novartis And Cohen: A View Into Pharma's Policy Concerns As Trump Took Office
As then-Novartis CEO Joe Jimenez worked with former Trump lawyer Michael Cohen on drug pricing issues, the pharma industry was preparing for the debate it's eventually getting to have.